Unresectable Intrahepatic Cholangiocarcinoma: Systemic Plus Hepatic Arterial Infusion Chemotherapy is Associated with Longer Survival in Comparison with Systemic Chemotherapy Alone

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2015 Dec 24

PMID 26695839

Citations 70

Authors

Ioannis T Konstantinidis

Bas Groot Koerkamp

Richard K G Do

Mithat Gonen

Yuman Fong

Peter J Allen

Michael I DAngelica

T Peter Kingham

Ronald P DeMatteo

David S Klimstra

Nancy E Kemeny

William R Jarnagin

Affiliations

Soon will be listed here.

Abstract

Background: Intrahepatic cholangiocarcinoma (ICC) is associated with poor survival. This study compared the outcomes of patients with unresectable ICC treated with hepatic arterial infusion (HAI) plus systemic chemotherapy (SYS) with the outcomes of patients treated with SYS alone.

Methods: Consecutive patients with ICC were retrospectively reviewed. Clinicopathologic data were reviewed. Survival rates were compared by Kaplan-Meier analysis and log-rank testing.

Results: Between January 2000 and August 2012, 525 patients with ICC were evaluated at Memorial Sloan Kettering Cancer Center, and 236 patients with unresectable tumors (locally advanced or metastatic) were analyzed. Disease was confined to the liver in 104 patients, who underwent treatment with combined HAI and SYS (n = 78 or 75%) or SYS alone (n = 26 or 25%). The response rate in the combined group was better than the rate in the group receiving SYS alone, although this did not reach statistical significance (59% vs 39%, P = .11). Overall survival for the combined group was longer than overall survival for the patients who received SYS alone (30.8 vs 18.4 months, P < .001), and this difference was maintained when patients with portal lymph node disease were included in the survival analysis (29.6 months with HAI and SYS [n = 93] vs 15.9 months with SYS [n = 74], P < .001). Eight patients who initially presented with unresectable tumors responded enough to undergo complete resection and had a median overall survival of 37 months (range, 10.4-92.3 months).

Conclusions: In patients with unresectable ICC confined to the liver or with limited regional nodal disease, a combination of SYS and HAI chemotherapy is associated with greater survival than SYS alone. Cancer 2016;122:758-765. © 2015 American Cancer Society.

Citing Articles

The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.

Cai Y, Wen W, Xia Y, Wan R Curr Oncol. 2025; 32(2).

PMID: 39996887 PMC: 11854701. DOI: 10.3390/curroncol32020087.

Management of intrahepatic cholangiocarcinoma: a review for clinicians.

Colangelo M, Di Martino M, Polidoro M, Forti L, Tober N, Gennari A Gastroenterol Rep (Oxf). 2025; 13:goaf005.

PMID: 39867595 PMC: 11769681. DOI: 10.1093/gastro/goaf005.

Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor.

Kaneko J, Kiuchi R, Takinami M, Ohnishi I, Ito J, Jindo O Clin J Gastroenterol. 2024; 17(5):936-942.

PMID: 38985249 PMC: 11436442. DOI: 10.1007/s12328-024-02014-w.

Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.

Yoo C, Hyung J, Chan S Liver Cancer. 2024; 13(2):119-135.

PMID: 38638168 PMC: 11023692. DOI: 10.1159/000531458.

Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers.

Zheng K, Wang X Ther Adv Med Oncol. 2024; 16:17588359231225040.

PMID: 38282664 PMC: 10822083. DOI: 10.1177/17588359231225040.

References

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

Mocellin S, Pilati P, Lise M, Nitti D . Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol. 2007; 25(35):5649-54. DOI: 10.1200/JCO.2007.12.1764. View

Mancini R, Tedesco M, Garufi C, Filippini A, Arcieri S, Caterino M . Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res. 2003; 23(2C):1837-41. View

Kerr D, McArdle C, Ledermann J, Taylor I, Sherlock D, Schlag P . Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003; 361(9355):368-73. DOI: 10.1016/S0140-6736(03)12388-4. View

Allen P, Nissan A, Picon A, Kemeny N, Dudrick P, Ben-Porat L . Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005; 201(1):57-65. DOI: 10.1016/j.jamcollsurg.2005.03.019. View

Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-8. PMC: 2083573. DOI: 10.1016/j.cgh.2007.05.020. View

Jiao Y, Pawlik T, Anders R, Selaru F, Streppel M, Lucas D . Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45(12):1470-1473. PMC: 4013720. DOI: 10.1038/ng.2813. View

Park J, Kim M, Kim K, Park D, Moon S, Song T . Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver. 2010; 3(4):298-305. PMC: 2852727. DOI: 10.5009/gnl.2009.3.4.298. View

Kemeny N, Capanu M, DAngelica M, Jarnagin W, Haviland D, Dematteo R . Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009; 20(7):1236-41. PMC: 9724731. DOI: 10.1093/annonc/mdn769. View

10.

Brown D, Geschwind J, Soulen M, Millward S, Sacks D . Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. 2006; 17(2 Pt 1):217-23. DOI: 10.1097/01.RVI.0000196277.76812.A3. View

11.

Kemeny N, Jarnagin W, Capanu M, Fong Y, Gewirtz A, DeMatteo R . Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2010; 29(7):884-9. PMC: 3646323. DOI: 10.1200/JCO.2010.32.5977. View

12.

Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R . Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005; 103(7):1402-7. DOI: 10.1002/cncr.20964. View

13.

Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M . Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005; 23(22):4888-96. DOI: 10.1200/JCO.2005.07.100. View

14.

Goere D, Deshaies I, De Baere T, Boige V, Malka D, Dumont F . Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010; 251(4):686-91. DOI: 10.1097/SLA.0b013e3181d35983. View

15.

Fiorentini G, Cantore M, Rossi S, Vaira M, Tumolo S, Dentico P . Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo. 2007; 20(6A):707-9. View

16.

Kemeny N, Niedzwiecki D, Hollis D, Lenz H, Warren R, Naughton M . Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006; 24(9):1395-403. DOI: 10.1200/JCO.2005.03.8166. View

17.

Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-7. DOI: 10.1053/jhep.2001.25087. View

18.

Sullivan R, NORCROSS J, WATKINS Jr E . CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION. N Engl J Med. 1964; 270:321-7. DOI: 10.1056/NEJM196402132700701. View

19.

Kemeny N, Schwartz L, Gonen M, Yopp A, Gultekin D, DAngelica M . Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?. Oncology. 2011; 80(3-4):153-9. PMC: 3123741. DOI: 10.1159/000324704. View

20.

Collins J . Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984; 2(5):498-504. DOI: 10.1200/JCO.1984.2.5.498. View